Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 8Breast Neoplasms 6Prostatic Neoplasms 5Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Lung Neoplasms 2Glioma 2Glioblastoma 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Metastatic Castration-sensitive Prostate Cancer 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Prednisone 3Abiraterone Acetate 3niraparib 2enzalutamide 2gallium 68 PSMA-11 1Rosuvastatin Calcium 1Pluvicto 1Pioglitazone 1Gonadotropin-Releasing Hormone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms, Castration-Resistant × niraparib × Clear all
NCT03748641 2026-06-05

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡